CRSP
Crispr Therapeutics AG
54.20$
-2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 5,090.3% | 817.9% | 170.3% | 3,641.9% | 61.9% | 37,469.7% | 11.1% | 25,286.7% | 35.2% | 315.0% | 6,637.0% | |
| – | -4,990.3% | -717.9% | -70.3% | 100.0% | 100.0% | -37,369.7% | 100.0% | -25,186.7% | 64.8% | -215.0% | -6,537.0% | |
| – | 5,090.3% | 817.9% | 170.3% | 3,641.9% | 61.9% | 30,790.3% | 48.0% | 105,881.9% | 104.7% | 916.2% | 7,559.2% | |
| – | 5,426.3% | 601.4% | 87.4% | 1,545.9% | 21.9% | 11,925.9% | 11.3% | 23,500.9% | 20.6% | 208.5% | 2,095.2% | |
| – | 10,516.6% | 1,419.3% | 257.7% | 5,187.8% | 83.9% | 11,925.9% | 59.1% | 129,208.0% | 124.9% | 1,118.0% | 9,654.4% | |
| – | -10,416.6% | -1,319.3% | -157.7% | -5,087.8% | 16.1% | -49,295.5% | 40.9% | -154,394.7% | -60.1% | -1,333.0% | -16,191.4% | |
| – | 43.7% | 155.9% | 0.0% | 0.0% | 8.7% | 887.2% | 2.6% | 10,741.5% | – | – | – | |
| – | -10,453.8% | -439.9% | -162.5% | -5,263.4% | 23.2% | -48,408.3% | 41.6% | -149,197.2% | -40.7% | -1,036.2% | -16,466.2% | |
| – | 2.8% | 9.4% | 4.3% | 17.7% | 0.2% | 112.5% | 0.2% | -74.5% | 0.8% | 10.2% | 103.5% | |
| – | -10,456.7% | -449.3% | -166.7% | -5,281.1% | 23.1% | -48,520.9% | 41.4% | -149,122.7% | -41.5% | -1,046.4% | -16,569.8% | |
| – | -10,358.7% | -264.7% | -150.3% | -4,975.2% | 17.8% | -48,018.2% | 42.9% | -148,850.7% | -35.4% | -981.2% | -15,911.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.